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AG-205 FOR THE TREATMENT OF BREAST 
CANCER 
SEQUENCE LISTING 
The instant application contains a Sequence Listing which 
has been submitted via EFS-Web and is hereby incorporated 
by reference in its entirety. Said ACSII copy, created on Jun. 
28, 2010, is named 10407260.txt and is 2,846 bytes in size. 
TECHNICAL FIELD 
Compositions, methods, and combination therapies for 
the treatment of cancers, including breast, colon, prostate, 
melanomas, lung cancer, and metastatic disease, are pro­
vided. Specifically, compositions comprising small mol­
ecule ligands to Pgrmc 1 are disclosed for use in treating and 
inhibiting tumor growth and progression and inhibition of 
metastases. The compositions and methods using these 
ligands can be used alone or in combination with other 
cancer treatment modalities. 
BACKGROUND OF THE INVENTION 
Cancer is one of the leading causes of death in the United 
States. The growth and spread of many cancers is driven by 
genes that are specifically activated in tumors. In many 
cases, these genes encode proteins involved in metabolism 
and signaling. Pgrmcl (progesterone receptor membrane 
component 1) is a low molecular weight (approximately 25 
kDa) protein that was originally thought to be a progesterone 
receptor. However, it has been demonstrated that Pgrmcl 
does not contain any homology to steroid receptors, but 
instead has homology to cytochrome bs- Pgrmcl binds to 
heme and has reducing activity, as the cytochrome proteins 
do. 
Pgrmcl is over-expressed in multiple types of cancer, 
including breast, thyroid, colon, ovary and lung cancer. 
Accordingly, Pgrmcl has great potential as a biomarker. In 
breast cancer, Pgrmcl phosphorylation corresponds with 
estrogen receptor status, and Pgrmcl levels correlate with 
tumor grade in ovarian cancer. Pgrmc 1 is also part of a gene 
signature that predicts hypoxia in breast cancer. Pgrmcl is 
also induced during dioxin-induced tumorigenesis and is 
part of a six gene signature associated with non-genotoxic 
carcinogens. 
2 
Multiple studies have indicated a role for Pgrmcl in cell 
signaling. The Pgrmcl sequence has binding sites for SH2 
and SH3 domain-containing proteins and consensus phos­
phorylation sites for tyrosine kinases. Our laboratory has 
also shown a more direct role for Pgrmcl in signaling. When 
damaged, breast cancer cells suppress death by sustaining 
signaling through multiple protein kinases, including the 
serine-threonine kinase Akt, and Pgrmcl promotes Akt 
activation. This work was subsequently verified by another 
10 group from Germany. Akt is activated by multiple pathways, 
including the stimulation of receptor tyrosine kinases. This 
led us to determine the extent to which Pgrmcl regulates 
receptor tyrosine kinases in cancer cells, and we have found 
that Pgrmcl binds to receptor tyrosine kinases and stabilizes 
15 them at the plasma membrane. 
Tyrosine kinases span the cell membrane and transmit 
signals from extracellular polypeptide hormones. Activation 
of the epidermal growth factor receptor (EGFR) signaling 
pathway has been linked to increased proliferation, angio-
20 genesis, metastasis and decreased apoptosis (Ritter et al., 
(2003) Semin Oneal, 30:3-11). The earliest studies with 
EGFR involved an activated form of the receptor expressed 
from transforming viruses (De Larco et al., (1980) J Biol 
Chem, 255:3685-3690), and EGFR is up-regulated in a 
25 variety of tumors, including colorectal cancer (72-82% ), 
head and neck cancer (95-100%), breast cancer (14-91%) 
and renal cell cancer (59-90% (Saloman et al., (1995) Crit 
Rev Oneal Hematol, 19:183-232). Furthermore, EGFR and 
HER2/neu over-expression are associated with a poor prog-
30 nosis in multiple tumor types (Brabender et al., (2001) Clin 
Cancer Res., 7: 1850-1855). 
EGFR is inhibited by a growing number of drugs, includ­
ing the antibody fragments cetuximab, matuzumab, nimo­
tuzumab, zalutumumab and panitumumab and the small 
35 molecule inhibitors erlotinib (Tarceva/OSI-774) and gefi­
tinib (Ono et al., (2006) Clin Cancer Res, 12:7242-7251; 
Bareschino et al., (2007) Ann Oneal, 18 Suppl 6:vi35-41). 
EGFR inhibitors have promise for treating cancer, but there 
effectiveness has been limited clinically. EGFR inhibitors 
40 such as erlotinib are effective only in a subset of patients that 
express mutated forms of the receptor. The most prominent 
group of patients with these mutations is females that have 
never smoked, leaving many patients with few therapeutic 
options. A method of inhibiting the progression of cancers is 
45 needed, which utilizes small molecule ligands to Pgrmcl. 
SUMMARY OF THE INVENTION 
These findings are important because they indicate that 
Pgrmcl is induced during tumor formation and is up­
regulated in tumors in the clinic. One important function of 50 
Pgrmcl in cancer is in chemotherapy resistance. The yeast 
Pgrmcl homologue, Dapl (damage-associated protein), was 
identified through its role in resistance to chemotherapy. In 
cancer cells, Pgrmcl regulates survival in response to che­
motherapeutic drugs, both in breast and ovarian cancer cells. 55 
One aspect of the present invention provides a method for 
inhibiting tumor growth and/or metastatic progression and/ 
or development of metastases comprising administering a 
ligand to Pgrmcl to a subject in need thereof in an amount 
sufficient to inhibit tumor growth and/or metastases. One 
mechanism of action for the ligand is destabilizing EGFR at 
the plasma membrane, and other target proteins may apply. 
The ligand may be AG-205. The tumor may be any tumor, 
including a solid tumor, such as a breast, colon, lung or 
prostate cancer, a lenkemia, melanoma or a lymphoma. The 
tumors may be primary lesions or metastatic lesions. 
Like cytochrome proteins, Pgrmcl binds to heme and to 
P450 proteins, a large class of proteins that are important in 
drug metabolism, hormone synthesis and metabolism, and 
lipid synthesis. Pgrmcl also binds to the cholesterol regu­
lators Insig (insulin-induced gene) and Scap (sterol regula- 60 
tory element binding protein cleavage activating protein), 
and to the RNA binding protein PAIR-BPI (plasminogen 
activator inhibitor 1 mRNA binding protein), although its 
biological roles in these interactions is unclear. Indeed, 
Pgrmcl does not regulate cholesterol synthesis in cancer 65 
cells and has a minimal effect on P450 activity. In contrast, 
Pgrmcl has an important role in cell signaling. 
The subject may be administered AG-205 in an amount of 
about 1 mg/kg subject weight to about 100 mg/kg subject 
weight. The tumor may be any solid tumor, such as a breast 
tumor, and the subject may thus be administered AG-205 
after surgical excision of the tumor. The subject may be 
further subjected to surgery, isolated limb perfusion, 
regional chemotherapy infusion, systemic chemotherapy, or 
immunotherapy or antisera to treat the tumor. 
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Regional chemotherapy infusion or the systemic chemo­
therapy may comprise at least one chemotherapeutic agent 
selected from the group consisting of: dacarbazine, carmus­
tine, lomustine, tauromustine, fotemustine, semustine, cis­
platin, carboplatin, vincristine, vinblastine, vindesine, taxol, 5 
dibromodulcitol, detorubicin, doxorubicin, cyclophosph­
amide, etoposide, piritrexim, and interferon. 
The metastases may be a metastasis to brain, lung, liver, 
peritoneal cavity or bone. The tumor may be further treated 
with one or more chemotherapeutic agents and/or radio- 10 
therapy. 
A further aspect of the present invention provides a 
combination therapy for inhibiting tumor growth and/or 
metastatic progression and/or development of metastases 
administering a ligand to Pgrmcl to a subject in need thereof 15 
in an amount sufficient to inhibit tumor growth and/or 
metastases, wherein the ligand destabilizes EGFR and a 
chemotherapeutic, and further administering an immuno­
therapeutic, and/or radiation therapy. 
The ligand may be AG-205 or a derivative. The ligand 20 
may be administered intravenously, intrathecally, or subcu­
taneously to a subject in need thereof. AG-205 may be 
administered in any appropriate amount, for example in 
amount of about 1 mg/kg subject weight to about 100 mg/kg 
subject weight. The ligand may be administered daily, 25 
weekly, or monthly. 
BRIEF DESCRIPTION OF DRAWINGS 
4 
days 1-7 after serum withdrawal. Solid lines represent 
control cells, while Pgrmcl-inhibited cells are indicated by 
a dashed line. Measurements were in triplicate, and the 
results are representative of three separate experiments. (B) 
The cell cycle profiles A549/con and A549/RNAi cells were 
analyzed by FACS 24 hours after serum deprivation, and 
there was a small but significant increase in the G1 popula­
tion in A549/RNAi cells and a corresponding decrease in S 
and G/M populations. (C) Western blot showing the expres­
sion of the inactive mutant Pgr-hbd (heme binding-deficient) 
in cells infected with the Ad-Pgr-hbd adenovirus (lane 2), 
but not in cells infected with the same dose of control 
Ad-Lacz adenovirus (lane 1). (D) Viability in Ad-Lacz 
(solid lines) and Ad-Pgr-hbd-infected cells (dashed lines), 
measured by cell counting 1-7 days after infection in media 
lacking serum. (E) Western blot demonstrating Pgrmcl 
inhibition by siRNA transfection in MDA-MB-468 cells. (F) 
Viability of MDA-MB-468 cells transfected with a control 
siRNA (solid line) or Pgrmcl-targeting siRNA ( dashed line). 
Measurements were in triplicate, and the results are repre­
sentative of triplicate repeats. 
FIG. 4 shows that the AG-205 compound binds to Pgrmcl 
and inhibits tumor cell viability. (A) Pgrmcl (SEQ ID NO: 
7) shares homology with AtMAPR2 (SEQ ID NO: 8)
(underlined residues), which was the target for a screen for
small molecule ligands. The putative heme-binding Tyr106
and Tyr112 are indicated with black boxes. (B) The molecu­
lar structure of AG-205 includes multiple aromatic compo­
nents. (C) Spectroscopic scan of Pgrmcl with vehicle con-
FIG. 1 shows that Pgrmcl increases tumor growth in 
mouse xenografts. A549 cells were infected with a lentivirus 
derived from the pGIPZ plasmid (A549/con) or a lentivirus 
containing pGIPZ expressing a short hairpin RNA targeting 
Pgrmcl (A549/RNAi). Athymic nude mice were injected 
with A549/con or A549/RNAi cells. (A) Western blot analy­
30 trol compared with vehicle plus 50 OM AG-205. The 
decrease in relative absorbance at 400 nm is consistent with 
an AG-205-induced change in the spectral properties of 
Pgrmcl-heme. The scan is representative of four separate 
scans using different Pgrmcl protein preparations. The 
35 lower scan is a comparison of purified Pgrmcl without and 
with the vehicle control (DMSO). Panels D (A549 cells) and 
E (MDA-MB-231 cells) are viability assays of cells main­
tained in 0.1 % serum (solid line) or 10% serum (dashed line) 
and treated with increasing doses of AG-205. Percent viabil-
sis revealed that Pgrmcl expression was inhibited in the 
excised A549/RNAi tumors (upper panel, lane 2), while 
ku70 was unchanged. (B) The excised tumor weight of 
A549/con was 2.9-fold greater than A549/RNAi. The results 
support a model in which Pgrmcl promotes in vivo tumor 
growth. (C) A549/con cells efficiently colonized the lungs 
after tail vein injection (upper panels, fluorescent image on 
left and bright field on right), while A549/RNAi cells were 
deficient in lung colonization (lower panels). The results 
from part C were quantitated and are presented graphically 45 
in panel D. (For all figures, *=s0.05; **=s0.01; and 
***=s0.005.) These results show that Pgrmcl increases in 
vivo tumor growth both as sub-cutaneous tumors and 
extravasated nodes in the lung. 
40 ity was determined by cell counting, and "% viability" refers 
to the cell number relative to the untreated control. The 
results show a highly significant loss of viability after 
AG-205 treatment when cells are grown in the absence of 
serum growth factors. 
FIG. 5 shows that a Pgrmcl ligand induces cell cycle 
arrest in a Pgrmcl-dependent manner. (A) Graph of tripli­
cate FACS analysis. AG-205-treated cells (right columns) 
had a significant G 1 arrest and accumulation of sub-G 1 cells, 
while S and G2/M-phase cells were depleted from the treated 
FIG. 2 shows that Pgrmcl regulates anchorage-indepen­
dent growth and migration, two key activities of tumor cells. 
(A) In a soft agar growth assay, which measures anchorage­
independent growth, a box plot demonstrates increased
colony size in A549/con compared to A549/RNAi cells.
Range is indicated by a vertical line, while 95% confidence
intervals are indicated by boxes. (B) A549/con cells formed
robust colonies in soft agar (left panel), while the colonies
arising from A549/RNAi cells were significantly smaller
(right panel). In panel C, the migration of A549/con and
A549/RNAi cells were measured using the Boyden chamber
assay, demonstrating a significant (P=0.002) decrease in
migration in the absence of Pgrmcl. Each of the assays was
performed in triplicate and is representative of multiple
independent experiments.
FIG. 3 shows that Pgrmcl promotes proliferation in the 
absence of serum in cancer cells. (A) Viability in A549/con 
and A549/RNAi cells was measured by cell counting from 
50 population. (B) Protein expression was analyzed by western 
blot for Pgrmcl (top) and ku70 (bottom). Cells were treated 
with O (lanes 1), 2 (lanes 2), 10 (lanes 3) or 50 (lanes 4) µM 
AG-205 for 24 hours. The results show that the Pgrmcl 
ligand AG-205 increases Pgrmcl expression in A549 cells. 
55 (C-D) The panels show western blots of phosphorylated 
ERKl/2 (upper panels) and total ERKl/2 (lower panels) The 
lanes in panel C are A549/con (lane 1 ), A549/RNAi (lane 2), 
A549/LacZ (lane 3) and A549/PGR-hbd cells (lane 4) fol­
lowing 48 hours serum starvation. The cells infected with 
60 adenovirus were similar to those described in FIG. 3, panels 
C and D. In panel D, A549 cells were treated with vehicle 
(lane 1) or 20 µM AG-205 (lane 2) for 24 hours in serum-free 
media. (E) A549/con (solid line) or A549/RNAi (dashed 
line) cells were treated with increasing doses of AG-205 for 
65 72 hours and viability was measured by counting, and "% 
viability" refers to the cell number relative to the untreated 
control. (F) Cells expressing Lacz (solid line) or the 
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Pgrmcl-hbd heme binding-deficient mutant (dashed line), 
were treated with increasing doses of AG-205. The Pgrmcl 
inhibitor partially reversed the loss of viability characteristic 
of Pgrmcl-hbd-expressing cells. Percent viability was deter­
mined by cell counting, and "% viability" refers to the cell 5 
number relative to the untreated control. For each experi­
ment, the results are representative of experiments per­
formed at least in duplicate. 
FIG. 6 shows that Pgrmcl promotes EGFR inhibitor 
sensitivity. (A) A549/con (solid line) or A549/RNAi (dashed 10 
line) cells were maintained in media lacking serum and 
treated with 2.5-10 µM of the EGFR inhibitor AG1478 for 
96 hours. Percent viability was determined by cell counting, 
and for all of the panels "% viability" refers to the cell 
density relative to untreated cells. (B) AG 14 78 susceptibility 15 
in Ad-Lacz and Ad-Pgr-hbd-infected A549 cells, measured 
by MTT assay 4 days after infection in serum-free media 
containing increasing doses of AG-1478. Solid lines repre­
sent cells infected with the control Ad-Lacz, while Ad-Pgr­
hbd-infected cells are indicated by a dashed line. (C) A549 20 
cells were treated with vehicle (solid line) or 10 µM AG-205 
( dashed line) plus increasing doses of erlotinib and counted. 
(D) MDA-MB-231 breast cancer cells were treated with
AG-205 and erlotinib as described in panel C. Each of the 
experiments is representative of experiments performed at 25 
least in triplicate. The results indicate that increases in 
proliferation in Pgrmcl-expressing cells are reversed by 
EGFR inhibitors. 
6 
MDA-MB-468 cells were treated with increasing doses of 
the Pgrmcl ligandAG-205. Protein expression was analyzed 
by western blot for EGFR (K) and ku70 (L). Cells were 
treated with O (lanes 1), 2 (lanes 2), 10 (lanes 3) or 50 (lanes 
4) µM AG-205 for 24 hours in serum-free medium. In panels
M-N, A549 cells were treated with the same doses and
analyzed for EGFR (M) and ku70 (N). The results show that
the Pgrmcl ligand AG-205 decreases EGFR protein levels.
Expression analyses were repeated at least in duplicate
throughout.
DETAILED DESCRIPTION OF THE 
INVENTION 
As used throughout the specification and the appended 
claims, the terms listed below have the following meanings, 
wherein "a" means one or more: 
By "EGFR" is meant epidermal growth factor receptor. 
By "RTK" is meant receptor tyrosine kinase. 
By "Pgrmcl" is meant progesterone receptor membrane 
component 1. 
By the term "subject" or "patient" as used herein is meant 
to include a mammal. The mammal can be a canine, feline, 
primate, bovine, ovine, porcine, camelid, caprine, rodent, or 
equine. Preferably the mammal is human. 
The term "efficacy" as used herein refers to the effective­
ness of a particular treatment regime. Efficacy can be 
measured based on such characteristics (but not limited to 
these) as inhibition of tumor growth, reduction of tumor FIG. 7 shows that EGFR and Pgrmcl co-precipitate and 
co-localize. (A) EGFR was precipitated with the antibody 
IMC-C225 from serum-starved A549 cells and probed for 
EGFR (top panel) or Pgrmcl (second panel). Lane 1 is a 
control precipitation with an irrelevant antibody. (B) For the 
inverse experiment, Pgrmcl was precipitated from A549 
cells with pre-immune serum (PIS, lane 1) or an anti-Pgrmcl 
antibody (a-Pgr, lane 2). EGFR was detected in the latter 
reaction (lower panel). (C) EGFR was immuno-precipitated 
from serum-starved A549/con (lane 1) or A549/RNAi (lane 
30 mass, reduction of metastatic lesions as assessed, for 
example, by radiologic imaging, slowed tumor growth, lack 
of detectable tumor associated antigens, and the like. Addi­
tional methods of assessing tumor progression are discussed 
herein and would be kuown to the treating and diagnosing 
35 physicians. 
By the phrases "pharmaceutically acceptable carrier" and 
"pharmaceutically acceptable excipient" are intended to 
mean any compound(s) used in forming a part of the 
formulation that is intended to act merely as a carrier, i.e., 
40 not intended to have biological activity itself. The pharma­
ceutically acceptable carrier or excipient is generally safe, 
non-toxic, and neither biologically nor otherwise undesir­
able. A pharmaceutically acceptable carrier or excipient as 
used herein includes both one and more than one such carrier 
2) cells. Immuno-precipitation reactions were probed for
EGFR (top) or Pgrmcl (bottom). (D) EGFR was immuno­
precipitated with IMC-C225 from MDA-MB-231 breast 
cancer cells, and precipitation reactions were analyzed by 
western blot for EGFR (upper panel) or Pgrmcl (lower 
panel). (E) The upper panels show fluorescence of Pgrmcl­
GFP expressed in A549 cells and immunofluorescence for 45 
EGFR, which was detected with a rhodamine-labelled sec­
ondary antibody. The lower panel shows a merged image, 
indicating that Pgrmcl and EGFR co-localize to an intrac­
ellular region adjacent to the nuclear membrane. The bar 
indicates 25 µm. 
or excipient. 
The terms "treating", and "treatment", and the like are 
used herein to generally mean obtaining a desired pharma­
cological and physiological effect. More specifically, the 
reagents described herein which are used to treat a subject 
50 with a tumor and metastatic disease generally are provided 
in a therapeutically effective amount to achieve any one or 
more of the following: inhibited tumor growth, reduction in 
tumor mass, loss of metastatic lesions, inhibited develop-
FIG. 8 shows that Pgrmcl increases EGFR levels in 
MDA-MB-468 breast cancer cells. Panel A is a diagram 
indicating the positions of the siRNA molecules targeting 
Pgrmcl. Exons 1, 2 and 3 are indicated by "ex". MDA-MB-
468 cells were transfected with a control siRNA (siCON, 55 
lanes 1 and 3) or two separate siRNAs targeting Pgrmcl 
(siPGR and siPGR2, lanes 2 and 4, respectively). In panels 
B-E and H-L, protein levels were analyzed by western blot
for EGFR (B), phospho-tyrosine (C), Pgrmcl (D) and ku70
(E), as a control for protein loading. Panels F-H show 60 
western blot analyses for (F) IGF-lR, (G) c-Kit and (H) tfR.
In panels I and J, transcript levels were analyzed by reverse
transcriptase-PCR for EGFR (I) and Pgrmcl (J). The top
band indicates the gene of interest, while actin primers were
included in the same reaction as a control for cDNA loading. 65 
The results show that Pgrmcl regulates EGFR protein levels
with little effect on EGFR transcription. In panels K-L,
ment of new metastatic lesions after treatment has started, or 
reduction in tumor such that there is no detectable disease 
(as assessed by e.g., radiologic imaging, biological fluid 
analysis, cytogenetics, fluorescence in situ hybridization, 
immunocytochemistry, colony assays, multiparameter flow 
cytometry, or polymerase chain reaction). The term "treat­
ment", as used herein, covers any treatment of a disease in 
a mammal, particularly a human. 
By "therapeutically effective amount" is meant an amount 
of an agent, reagent, compound, composition, or combina­
tion of reagents disclosed herein that when administered to 
a mammal is sufficient to be effective against the tumor. 
By the term "tumor" is meant to include both benign and 
malignant growths or cancer. Thus, the term "cancer", unless 
US 9,724,337 B2 
7 
otherwise stated, can include both benign and malignant 
growths. Preferably, the tumor is malignant. The tumor can 
be a solid tissue tumor such as a melanoma, or a soft tissue 
tumor such as a lymphoma, a leukemia, or a bone cancer. 
By the term "primary tumor" is meant the original neo- 5 
plasm and not a metastatic lesion located in another tissue or 
organ in the patient's body. 
8 
Pgrmcl homologue from the flowering plant Arabidopsis 
thaliana. AG-205 was found to bind to At Pgrmcl, but no 
subsequent research was conducted on the biochemical or 
biological activity of AG-205. It was found that AG-205 is 
toxic to multiple cancer cell lines from lung, breast, colon 
and prostate tissues. Any cell line over-expressing Pgrmcl 
may be targeted by AG-205, due to the role of Pgrmcl in 
promoting cell signaling. Indeed, AG-205 is most active 
when serum is absent, likely because cells are deprived of 
By the terms "metastatic disease", "metastases", and 
"metastatic lesion" are meant a group of cells which have 
migrated to a site distant relative to the primary tumor. 10 super-physiological levels of growth factors and require 
Pgrmcl for efficient survival signaling. AG-205 may be 
limited by its solubility, and thus derivatives of AG-205 are 
included herein, as optimized for their enhanced solubility, 
Receptor tyrosine kinases were among the first proto­
oncogenes ever identified. Alterations in RTKs, such as 
EGFR and HER2/neu, are associated with a variety of 
cancers. RTK inhibitors such as herceptin, erlotinib and 
iressa are currently among the most promising agents in 15 
development for treating cancer, and they extend both 
overall survival and disease-free progression in some 
patients. RTK inhibitor treatments do not have the harsh side 
effects associated with traditional chemotherapy. However, 
patients do not respond uniformly to these RTK inhibitors, 20 
and comprehensive genetic screening of every cancer patient 
will likely be expensive and complex. 
Pgrmc 1 (progesterone receptor membrane component 1) 
is a protein that is up-regulated in multiple types of cancer, 
including breast, lung, colon and ovarian cancer. Pgrmcl 25 
binds to heme and stimulates the activity of P450 proteins, 
which catalyze many critical reactions in lipid and hormone 
synthesis. It has been previously shown that Pgrmcl regu­
lates protein kinase signaling downstream from EGFR, and 
the role of Pgrmcl in activating EGFR has been investi- 30 
gated. Pgrmcl was inhibited in A549 human lung cancer 
cells and MDA-MB-468 human breast cancer cells by a 
combination of siRNA and shRNA expression directed from 
a lentivirus. Pgrmcl inhibition caused a 4-25-fold decrease 
in EGFR levels. This drop in EGFR was accompanied by a 35 
27-40% decrease in proliferation in MDA-MB-468 and
A549 cells. Pgrmcl also caused a 2.9-fold drop in anchor­
age-independent growth and 4.1-fold inhibited migration in 
A549 cells. In both cell types, Pgrmcl inhibition had no 
effect on EGFR transcription, indicating that the effect was 40 
post-translational. Pgrmcl bound to caveolin, a membrane 
protein that binds to cholesterol and receptor tyrosine 
kinases. Finally, a Pgrmcl ligand de-stabilized EGFR and 
induced cell death in multiple tumor cell lines. 
Pgrmcl is a component of a hormone/drug receptor 45 
complex that is over-expressed in tumors and stabilizes 
RTKs. Furthermore, new Pgrmcl inhibitors de-stabilize 
EGFR through a distinct mechanism from other agents and 
could be used in combinations with multiple existing drugs. 
This could provide a new therapeutic option in the clinic for 50 
cancer patients that have developed resistance to currently 
available drugs. 
It has been found that Pgrmcl directly associates with 
EGFR in lung and breast cancer cells, as well as in cells of 
other cancer types. Inhibition of Pgrmcl causes EGFR 55 
levels to diminish at the plasma membrane, likely due to 
defective trafficking to the plasma membrane or increased 
endocytosis from the plasma membrane. By stabilizing 
EGFR at the plasma membrane, Pgrmcl increases the sen­
sitivity of lung cancer cells to the EGFR inhibitor erlotinib, 60 
underscoring the importance of Pgrmcl in EGFR function. 
Furthermore, genetic inhibition of Pgrmcl de-stabilizes 
EGFR in breast cancer cells expressing high levels ofEGFR, 
suggesting multiple routes through which Pgrmcl affects 
EGFR function. 65 
The small molecule ligand of Pgrmcl, called AG-205, 
was identified in 2005 using an in silica screen with the 
specificity and delivery. 
Receptor Tyrosine Kinases as Cancer Therapeutic Targets 
Receptor tyrosine kinases (RTKs) were originally discov­
ered through their association with cancer. EGFR has been 
identified as regulating RTK stability and activation. 
EGFR (Erb-Bl) is part of a family of proteins that 
includes Erb-B2/HER2/neu, Erb-B3/HER3 and ErbB4/ 
HER4. Activation of the EGFR signaling pathway has been 
liuked to increased proliferation, angiogenesis, metastasis 
and decreased apoptosis (Ritter et al., (2003) Semin Oneal 
30(1 Suppl 1):3-11). At least five mitogenic growth factors 
bind and activate EGFR: EGF, TGF-a, amphiregulin, hepa­
rin-binding EGF and epiregulin. The earliest studies with 
EGFR involved an activated form of the receptor expressed 
from transforming viruses (De Larco et al., (1980) The 
Journal of Biological Chemistry 255(8):3685-3690; Down­
ward et al., (1984) Nature 307(5951):521-527), and c-EGFR 
and HER2/neu can transform NIH-3T3 cells (Di Fiore et al. 
(1987) Cell 51(6):1063-1070). EGFR is up-regulated in a 
variety of tumors, including colorectal cancer (72-82% ), 
head and neck cancer (95-100%), breast cancer (14-91%) 
and renal cell cancer [59-90% (Salomon et al., (1995) Crit 
Rev Oneal Hematol 19(3):183-232)]. Furthermore, EGFR 
and HER2/neu over-expression are associated with a poor 
prognosis in multiple tumor types [(Brabender et al., (2001) 
Clin Cancer Res 7(7):1850-1855), reviewed in (Ono et al., 
(2006) Clin Cancer Res 12(24):7242-7251)]. EGFR is acti­
vated by a number of mechanisms, including over-expres-
sion, amplification and activating mutations Sebastian et al., 
(2006) Biochim Biophys Acta 1766(1):120-139). 
EGFR is inhibited by the drug erlotinib (Tarceva/OSI-
774), a quinazoline-based agent which associates with the 
ATP binding region of EGFR (Bareschino et al., (2007) Ann 
Oncol 18 Suppl 6:vi35-41). Erlotinib was approved by the 
FDA in 2004 for the treatment of chemotherapy-resistant 
advanced NSCLC following a 731 patient multicenter phase 
III trial in which erlotinib significantly improved overall 
survival and progression-free survival in NSCLC patients 
after one or two chemotherapy regimens had failed. 
One promising strategy with EGFR inhibitors appeared to 
be combining them with other drugs. However, clinical trials 
combining EGFR inhibitors with chemotherapy have not yet 
been successful (Herbst et al., (2005) J Clin Oneal 23(25): 
5892-5899). EGFR and Src inhibitors are a promising com­
bination for head and neck cancer (Koppikar et al., (2008) 
Clin Cancer Res 14(13):4284-4291). Thus, erlotinib and 
other targeted therapeutics have promise for treating cancer, 
but in clinical terms, the responses are far from complete. 
One approach to more effective targeting of these inhibitors 
is to design drug combinations that accommodate the regu­
lation and trafficking of EGFR in lung cancer cells. 
Another strategy is to identify patients with the greatest 
potential of benefiting from EGFR inhibitors. Cell lines 
exhibit markedly different responses to EGFR inhibitors 
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(Ono et al., (2006) Clin Cancer Res 12(24):7242-7251), a 
fact that probably reflects the cells' genetic backgrounds. 
Where EGFR performs an essential function in proliferation 
and survival, the drugs are highly effective. In other back­
grounds, the benefits of the drugs are limited. Responsive- 5 
ness to EGFR inhibitors is difficult to predict. Tumors 
harboring EGFR activating mutations respond well to EGFR 
inhibitors, but some tumors expressing mutant EGFR are 
inhibitor-resistant (Reinmuth et al., (2006) Int J Cancer 
119(4):727-734). In addition, some tumors with amplified 10 
EGFR have increased sensitivity to EGFR inhibitors. 
Recently, there has been increasing interest in blocking 
RTK function by inhibiting their processing, and inhibitors 
of glycosylation and chaperones are effective at disrupting 
RTK function and drug resistance (Contessa et al., (2008) 15 
Cancer Res 68(10):3803-3809). 
Pgrmc 1 (progesterone receptor membrane component 1) 
10 
expression increased in advanced stage tumors, and Pgrmcl 
was homogeneously expressed within the tumors (Peluso et 
al., (2008) J Clin Endocrinol Metab 93(5):1592-1599). 
Microarray analyses have also detected Pgrmcl expression 
in colon, lung, ovarian and breast tumors (Difilippantonio et 
al., (2003) Eur J Cancer 39(13):1936-1947). 
Yeast cells lacking the Pgrmcl homologue, Dapl, are 
sensitive to DNA damage (Craven et al., (2007) J Biol Chem 
282(50):36543-36551) due to a failure in a repair process. 
Like Pgrmcl, Dapl binds to heme (Ghosh et al., (2005) 
Biochemistry 44(50):16729-16736), and heme binding is 
essential for damage resistance (Mallory et al., (2005) Mal 
Cell Biol 25(5):1669-1679). Furthermore, exogenous heme 
or over-expression of the heme synthetic pathway can over­
come the requirement for Dapl in damage resistance J Biol 
Chem 282(50):36543-36551). 
Because of the role of Dapl in damage resistance, 
whether Pgrmcl has an analogous function in cancer cells 
was tested. Pgrmcl was inhibited by expression of a domi­
nant-negative, heme binding-deficient mutant or by siRNA, 
and either treatment sensitized breast cancer cells to the 
chemotherapeutic drugs doxorubicin and camptothecin 
(Crudden et al., (2006) J Pharmacol Exp Ther 316(1):448-
455). These drugs are inhibitors of topoisomerase II and 
topoisomerase I, respectively. Peluso, et al. reported similar 
results in ovarian cancer cells treated with cisplatin (Peluso 
et al., 2008). Pgrmcl expression is induced by chemo­
therapy (Crudden et al., 2006) and in mouse cells with short 
telomeres (Franco et al., (2005) Carcinogenesis 26(9): 1613-
1626), which suffer chromosomal damage during senes­
cence and crisis. These results suggest that Pgrmcl induc­
tion is a consequence of DNA damage, and Pgrmc 1 plays a 
role in suppressing damage-induced cell death in cancer 
cells. 
is a member of a multi-protein progesterone-binding com­
plex (Meyer et al., (1996) Eur J Biochem 239(3):726-731), 
and Pgrmcl has also been named Hpr6.6 [human membrane 20 
progesterone receptor (Gerdes et al., (1998) Biol Chem 
379(7):907-911)]. Pgrmcl does not bind directly to proges­
terone (Min et al., (2005) Febs J 272(22):5832-5843) and 
has no homology with steroid receptors (Mifsuf et al., 
(2002) Genome Biol 3(12):RESEARCH0068), nuclear or 25 
membrane-associated. Instead, Pgrmcl resides in the endo­
plasmic reticulum (Crudden et al., (2005) Tumour Biol 
26(3):142-146), where it binds to various proteins impli­
cated in lipid metabolism, including caveolin/Cavl, Insig-1 
(insulin-induced gene), Scap (SREBP cleavage activating 30 
protein) and P450 proteins (Bramley et al., (2002) Domest 
Anim Endocrinol 23(1-2):3-12). These findings suggest a 
model in which a multi-protein Pgrmcl complex responds to 
changes in lipid and/or hormone levels and transports sig­
naling proteins to the cell membrane. 35 Ligands for the Pgrmcl Heme Binding Site 
The endogenous Pgrmcl ligand is heme (Crudden et al. 
(2006) J Pharmacol Exp Ther 316(1):448-455). Pgrmcl 
shares key structural motifs with cytochrome b5 (Mifsud 
2002), a heme binding protein that activates cytochrome 
P450 proteins Pharmacology & therapeutics 97(2): 139- 40 
152). Pgrmcl binds and activates P450 proteins (Hughes et 
al., (2007) Cell Metab 5(2):143-149), which metabolize 
drugs, hormones and lipids. Heme is also implicated in Cavl 
function, because Cavl binds to several heme-containing 
proteins, including heme oxygenase (Jung et al., (2003) 45 
IUBMB Life 55(9):525-532) and NOS (Garcia-Cardena et 
al., (1997) The Journal of biological chemistry 272(41): 
25437-2544). 
The heme binding site of Pgrmcl is predicted to be a 
prominent groove at the center of the protein. Notably, all of 50 
the residues that are known to be important in heme binding 
cluster along one face of the protein. The Asp120 residue, 
which is required for heme binding (Crudden et al., 2006), 
is at the center of the groove. The Tyrl 07 and Tyr113 sites 
are required for heme binding and localize to the right of the 55 
groove. Interestingly, the Tyrl 13 site is a proposed phos­
phorylation site for the Ab! tyrosine kinase (Cahill (2007) J
Steroid Biochem Mal Biol 105(1-5):16-36), but this phos­
phorylation event has not been formally demonstrated. 
Finally, the Tyr164 residue, which is analogous to the 60 
Tyr138 of yeast, is required for heme binding and localizes 
to the side of the heme-binding groove. 
It has been shown that Pgrmcl stabilizes EGFR in human 
cancer cells. This follows on earlier findings that Pgrmcl is 
over-expressed in breast tumors and in cancer cell lines from 65 
the colon, thyroid, lung, and cervix (Crudden et al., (2005) 
Tumour Biol 26(3):142-146). In ovarian cancer, Pgrmcl 
Pgrmcl is unusual because it has both the characteristics 
of a cytochrome and a receptor, suggesting a regulatory 
point in metabolism. Yoshitani, et al. identified a novel class 
of Pgrmcl ligands by combining molecular modeling of the 
Arabidopsis thaliana Pgrmcl structure with binding assays 
using Pgrmcl immobolized on a Biocore chip ((2005) 
Proteomics 5( 6): 14 72-1480). A. thaliana is structurally con­
served with mammalian Pgrmcl in the heme-binding site, 
and the two proteins have a similar overall structure. While 
Yoshitani identified four Pgrmcl ligands and measured their 
binding affinity, they performed only biochemical assays 
and did not explore a physiological function for the ligands. 
Pgrmcl ligands are predicted to bind to the heme-binding 
crevice of Pgrmcl (Yoshitani et al., (2005) Proteomics 
5(6):1472-1480), suggesting that the ligands could displace 
heme from its binding site. Heme binding is critical for the 
activity of Pgrmcl homologues (Hughes et al., (2007) Cell 
Metab 5(2):143-149), suggesting that the Pgrmcl ligands 
would act as Pgrmcl inhibitors. The present invention 
provides a mechanism showing that these ligands inhibit 
EGFR stability and induce cell death in cancer cells. 
Receptor tyrosine kinases are among the most important 
proteins in cancer, driving the growth, survival and spread of 
tumor cells. A previously unknown step in RTK regulation 
has been identified, in which a heme-binding steroid recep­
tor component, Pgrmcl, stabilizes EGFR and promotes 
proliferation, anchorage-independent growth and invasion. 
It has previously been shown that Pgrmcl is over-expressed 
in tumors (Crudden et al. (2005) Tumour Biol 26:142-6), 
including breast tumors. Pgrmcl is induced by chemo­
therapy (Mallory et al., (2005) Mal Pharmacol 68:1747-56) 
and is implicated in chemotherapy resistance (Crudden et 
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al., (2006) J Pharmacol Exp Ther 316:448-55). However, 
many tumors express Pgrmcl prior to chemotherapy, sug­
gesting a function for Pgrmcl other than drug resistance. In 
fact, Pgrmcl activates Akt (Hand et al. (2003) J Cell 
Biochem 90:534-47), a pro-survival signaling kinase, in 5 
breast cancer cells. A novel Pgrmcl ligand has been iden­
tified that de-stabilizes EGFR and triggers cell death. 
Another potential mechanism through which Pgrmcl 
might stabilize EGFR is via an interaction with the PAIR­
BPl mRNA binding protein. The target of PAIR-BPI is the 10 
PAil protein, which is associated with tumor invasion and 
vascularization (Bajou et al. (1998) Nat Med 4:923-8). 
However, in Pgrmcl-inhibited cells, no change in PAil 
transcript levels was detected. This result does not support a 
model in which Pgrmcl stabilizes EGFR by altering PAil 15 
levels via binding to PAIR-BPI. However, the model that a 
Pgrmcl-PAIR-BPl complex stabilizes EGFR via an inter­
mediate other than PAil carmot be excluded. 
Because the predicted structure of Pgrmcl contains a 
well-defined ligand binding domain (Song et al., (2004) J 20 
Biomol NMR 30:215-8), the ability of a novel Pgrmcl ligand 
12 
erbitux/cetuximab and by the small molecule inhibitors 
erlotinib and gefitinib. However, the fraction of patients that 
responds to erlotinib is somewhat limited, and there are 
safety concerns with erlotinib as well (see the Food and 
Drug Administration website Medwatch for Tarceva (ww­
w.fda.gov /medwatch/ safety /2008/ safety08 .htm#Tarceva)). 
One of the curious features of AG-205 is that it is more 
active against cell lines expressing wild-type EGFR than the 
llE746-A750 mutant EGFR. In contrast, the llE746- A750 
mutant is more sensitive to erlotinib than cells expressing 
wild-type EGFR. Furukawa, et al. have shown that llE746-
A750 mutant EGFR in constitutively active and exhibits 
deficient Cb! binding, ubiquitination and endocytosis (Furu­
kawa et al., (2007) DNA Cell Biol 26: 178-85). Interestingly, 
it was found that there is an intracellular pool of EGFR in the 
early stages following AG-205 treatment in MDA-MB-468 
cells. Thus, one possible model is that Pgrmcl sustains 
EGFR at the cell membrane, and that llE746-A750 mutants 
do not require Pgrmcl for their membrane localization. 
In one aspect of the invention, the methods and compo-
sitions disclosed herein can be used to treat, inhibit or slow 
the progression of malignancies. These malignancies can be 
solid or soft tissue tumors. Soft tissue tumors, or liquid 
tumors, include bone cancers, lymphomas, and leukemias. 
25 Another aspect of the invention is to use the methods and 
compositions to inhibit or prevent metastases or metastatic 
to inhibit Pgrmcl was tested. AG-205 inhibited EGFR 
stability at micromolar levels, similar to the effect of Pgrmc 1 
inhibition by RNAi, and AG-205 induced cell death in 
cancer cells. This is surprising, because siRNA for Pgrmcl 
was not toxic. This suggests that other proteins related to 
Pgrmcl, including Pgrmc2 (Gerdes et al. (1998) Biol Chem 
379:907-11) and Neudesin/SPUF (Kimura et al., (2008) J 
Biol Chem 283:4323-31), may compensate for the loss of 
Pgrmcl following siRNA inhibition. Because these proteins 30 
have a similar heme-binding domain to Pgrmcl, they likely 
bind to AG-205. Alternately, AG-205 may bind to proteins 
other than Pgrmc 1 that are important in maintaining viability 
in cancer cells. 
The effect of a Pgrmcl ligand on EGFR levels and 35 
viability was also tested. The AG-205 compound was iden­
tified by Yoshitani, et al. ((2005) Proteomics 5(6):1472-
1480), who used a two-step process that began with com­
putational screening based on the NMR structure of an A. 
thaliana Pgrmcl homologue, called AtMAPR2 (A. thaliana 40 
membrane-associated progesterone receptor 2) or 
At2g24940. Pgrmcl contains 64% identity with AtMAPR2 
in two separate regions of the heme-binding domain, begin­
ning with residues Ala90 and Thr151. The screen for 
AtMAPR2 ligands began with modeling of the putative 45 
heme-binding site of AtMAPR2. From the computational 
screen, 69 compounds were selected for further testing with 
purified AtMAPR2 using surface plasmon resonance. The 
affinity characteristics of the top four candidates were then 
tested individually. All of the four highest affinity ligands 50 
had a similar structure, with aryl rings bridged by a short 
backbone. 
progression. 
Thus, an aspect of the invention is to treat tumors or 
metastatic disease with a ligand to Pgrmcl. These ligands 
can be used alone, in combination with each other, or in 
combination with other cancer modalities, such as but not 
limited to chemotherapy, surgery, radiotherapy, hyperther­
mia, immunotherapy, hormone therapy, biologic therapy 
( e.g., immune effector mechanisms resulting in cell destruc­
tion, cytokines, immunotherapy, interferons, interleukin-2, 
cancer vaccine therapy, and adoptive therapy), and drugs to 
ameliorate the adverse side effects of such cancer modalities. 
The term cancer embraces a collection of malignancies 
with each cancer of each organ consisting of numerous 
subsets. Typically, at the time of cancer diagnosis, "the 
cancer" consists in fact of multiple subpopulations of cells 
with diverse genetic, biochemical, immunologic, and bio­
logic characteristics. 
Preferred cancers to be treated by the present invention 
include but are not limited to melanomas (e.g., cutaneous 
melanoma, metastatic melanomas, and intraocular melano­
mas), prostate cancer, lymphomas (e.g., cutaneous T-cell 
lymphoma, mycosis fungicides, Hodgkin's and non-Hodg­
kin's lymphomas, and primary central nervous system lym-
phomas), leukemias (e.g., pre-B cell acute lymphoblastic 
leukemia, chronic and acute lymphocytic leukemia, chronic 
and acute myelogenous leukemia, adult acute lymphoblastic 
leukemia, mature B-cell acute lymphoblastic leukemia, pro­
lymphocytic leukemia, hairy cell leukemia, and T-cell 
There are four aromatic ligands for the Arabidopsis 
thaliana Pgrmcl homologue, AtMAPR2, which is highly 
conserved with human Pgrmcl in the heme-I domain. One 55 chronic lymphocytic leukemia), and metastatic tumors 
which exhibit these proteins on the cell surface. See Lynn D. 
Wilson et al., "Cutaneous T-Cell Lymphomas," in CAN­
CER: PRINCIPLES & PR ACTICE OF ONCOLOGY 2220-
of the AtMAPR2 ligands with the highest binding affinity is 
called AG-205 and is an aromatic compound. Based on the 
putative structure of Pgrmcl, the majority of the conserved 
residues cluster in a pocket that is analogous to the 
AtMAPR2 ligand binding site. Tyr106 and Tyr112 are 60 
required for heme binding. The addition of AG-205 to 
purified Pgrmcl caused a shift in absorbance at approxi­
mately 400 nm, with a smaller shift at approximately 530 
nm. The results suggest that AG-205 alters the spectroscopic 
properties of the Pgrmcl-heme complex. 
EGFR is one of the most prominent therapeutic targets in 
cancer, and is inhibited clinically by the antibody fragment 
2232 (Vincent T. DeVita, Jr. et al., editors, 5th ed. 1997); 
Bauk et al., 1999, J. Cutan. Pathol., 26(2): 65-71. For 
example, the cancer may be lung cancer. 
Once a tumor is diagnosed in a patient, the first question 
is whether the tumor has progressed and spread to the 
regional lymph nodes and to distant organs. In the end, most 
65 cancer deaths result from metastases that are resistant to 
conventional cancer therapies. Metastases can be located in 
different organs and in different regions of the same organ, 
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making complete eradication by surgery, radiation, drugs, 
and/or biotherapy nearly impossible. Also contemplated for 
treatment with the methods, combination therapies, and 
compositions disclosed herein is the treatment of metastatic 
cancer. Cancers typically begin their growth in only one 
location in the tissue of origin. As the cancer progresses, the 
cancer may migrate to a distal location in the patient. For 
example, a cancer beginning in the prostate may migrate to 
the lung. Thus, if a primary tumor is given enough time to 
14 
go through these steps, it will form metastatic lesions at a 10 
site or sites distant to the primary tumor. The reagents, 
methods, and combination therapies disclosed inhibit or 
prevent one or more of these steps in the metastatic process. 
For additional details on the mechanism and pathology of 
tumor metastasis, see Isaiah J. Fidler, "Molecular Biology of 15 
Cancer: Invasion and Metastasis," in CANCER: PRIN­
CIPLES & PRACTICE OF ONCOLOGY 135-152 (Vincent 
The lungs are the second most frequent site of metastatic 
disease. Anatomically, the lungs are vascular rich sites and 
the first capillary bed encountered by circulating tumor cells 
as they exit from the venous drainage system of their 
primary tumor. Thus, the lungs act as the initial filtration site, 
where disseminated tumor cells become mechanically 
trapped. However, the cells which get trapped there and go 
on to proliferate and form metastatic lesions will largely 
depend upon the original primary tumor from which they 
derive. This hematogenous process of lung metastases is the 
most common means, but pulmonary metastases can also 
occur via the lymphatic system. See Harvey I. Pass et al., 
"Metastatic Cancer to the Lung," in CANCER: PRIN­
CIPLES & PRACTICE OF ONCOLOGY 2536-2551 (Vin­
cent T. DeVita et al., editors, 5th ed., 1997). The most 
common primary tumors which go on to have lung metas­
tases include soft tissue sarcoma, colorectal carcinoma, 
germ cell tumors, osteosarcoma, certain pediatric tumors 
(e.g., rhabdomyosarcomas, Ewing's sarcomas, Wilm's 
tumor, liposarcomas, leiomyosarcomas, alveolar sarcomas, 
synovial sarcomas, fibrosarcomas, neurogenic sarcomas, 
and epithelial sarcomas), melanoma, renal cell carcinoma, 
and breast carcinoma. Most of the metastases from these 
T. DeVita et al., editors, 5th ed., 1997).
primary tumors are treated surgically. However, some rec-
Accordingly, one aspect of the invention provides meth­
ods of using and compositions comprising ligands to 20 
Pgrmcl, which are capable of destabilizing EGFR. A pre­
ferred ligand to Pgrmcl is AG-205. These ligands can be 
used alone or in combination with other agents or cancer 
treatment modalities that prevent metastases or inhibit pro­
gression of metastatic lesions. 25 ommend surgery in combination with chemotherapy. For 
example, germ cell tumors which have metastasized to the 
lung are treated with surgical resection following curative 
cisplatin-based combination chemotherapy. 
Another aspect of the invention contemplates the use of 
the ligands in combination with other conventional cancer 
treatment modalities, in the form of combination therapies. 
Many treatments exist for cancers. The particular cancer 
therapy or combination of therapy modalities used to treat a 30 
cancer depend greatly on the type of cancer, its stage, the 
patient (e.g., weight, sex, age, health, prior cancers, and the 
like), and where the patient is in therapy ( e.g., first treatment, 
Treatment of lung metastases frequently involves metas­
tasectomy (i.e., surgical removal of the lung metastatic 
lesion). Thus one aspect of the invention contemplates the 
use of the disclosed antibodies in combination with conven­
tional therapies, as discussed herein or as known in the art, 
for the treatment of lung metastases. in blast crisis, refractive to initial treatments, cancer relapse, 
Further, the present invention contemplates the use of 
ligands to Pgrmcl, able to destabilize a receptor tyrosine 
kinase such as EGFR. These ligands of interest preferably 
are administered in a physiologically acceptable carrier to a 
subject. The ligands may be administered in a variety of 
or a second cancer perhaps induced by the treatment of the 35 
first cancer months or years before). Therefore, physicians 
will frequently have to combine a variety of treatment 
modalities that will best suit the needs of the patient in 
combating the disease and the patient's self-determination of 
quality of life. 40 ways including but not limited to parenteral administration, 
including subcutaneous (s.c.), subdural, intravenous (i.v.), 
intramuscular (i.m.), intrathecal, intraperitoneal (i.p.), 
intracerebral, intraarterial, or intralesional routes of admin­
istration, localized ( e.g., surgical application or surgical 
Treatment modalities include but are not limited to sur­
gery, radiation therapy, chemotherapy, biologic therapy 
(e.g., cytokines, immunotherapy, and interferons), hormone 
therapies, and hyperthermia. Conventional chemotherapy 
can be further broken down into hormone therapies ( e.g., 
antiestrogens, aromatase inhibitors, gonadotropin-releasing 
hormone analogues, and anti-androgens), anti-tumor alky­
lating agents ( e.g., mustards, nitrosoureas, tetrazines, and 
aziridines ), cisplatin and its analogues, anti-metabolites 
(e.g., methotrexate, antifolates, 5-fluoropyrimidines, cytara­
bine, azacitidine, gemcitabine, 6-thipurines, and hydroxyu­
rea), topoisomerase interactive agents, antimicrotubule 
agents ( e.g., vinca alkaloids, taxanes, and estramustine ), 
differentiating agents (e.g., retinoids, vitamin D3, polar­
apolar compounds, butyrate and phenylactetate, cytotoxic 
drugs, cytokines, and combinations thereof), and other che­
motherapeutic agents such as fludarabine, 2-chlorodeoxy­
adenosine, 2'-deoxycoformycin, homoharringtonine (HHT), 
suramin, bleomycin, and L-asparaginase. 
Treatment of metastases may be with the compositions, 
combination therapies and methods described herein by 
themselves or in combination with other cancer treatment 
modalities depending on the site of the metastases and the 
primary tumor from which the metastases originates. The 
most common sites for tumors to metastasize are brain, lung, 
liver, bone, malignant pleural and pericardia! effusions, and 
malignant ascites. 
45 suppository), and pulmonary (e.g., aerosols, inhalation, or 
powder) and as described further below. Preferably, the 
ligands are administered intravenously or subcutaneously. 
Depending upon the manner of introduction, the ligands 
may be formulated in various ways. The concentration of 
50 therapeutically active ligand in the formulation (i.e., a for­
mulation that is therapeutically effective to the subject to 
which it was administered) may vary from about 0.01 
mg/mL to 1 g/mL. Preferably, the immunoglobulin compo­
sition, when administered to a subject in need thereof, 
55 reaches a concentration in the blood of the subject to whom 
it was administered of about 10 µg/mL or more. 
Preferably, the ligand is formulated for parenteral admin­
istration in a suitable inert carrier, such as a sterile physi­
ological saline solution. The dose administered will be 
60 determined by route of administration. Preferred routes of 
administration include parenteral, subcutaneous, or intrave­
nous administration. 
For parenteral administration, the ligands of the invention 
can be administered as injectable dosages of a solution or 
65 suspension of the substance in a physiologically acceptable 
diluent with a pharmaceutical carrier, which can be a sterile 
liquid such as water and oils with or without the addition of 
US 9,724,337 B2 
15 
a surfactant. Other acceptable diluents include oils of ani­
mal, vegetable, or synthetic origin, for example, peanut oil, 
soybean oil, and mineral oil. In general, glycols such as 
propylene glycol or polyethylene glycol (PEG) are preferred 
liquid carriers, particularly for injectable solutions. The 
ligands can be administered in the form of a depot injection 
or implant preparation, which can be formulated in such a 
manner as to permit a sustained release of the active ingre­
dient(s ). 
16 
The ligands of this invention can be administered in a 
sustained release form, for example a depot injection, 
implant preparation, or osmotic pump, which can be formu­
lated in such a manner as to permit a sustained release of the 
active ingredient. Implants for sustained release formula­
tions are well-known in the art. Implants are formulated as 
microspheres, slabs, etc. with biodegradable or non-biode­
gradable polymers. For example, polymers of lactic acid 
and/or glycolic acid form an erodible polymer that are 
According to one aspect of the invention, the ligand of 
interest may be administered alone, or in combination with 
other agents as discussed above to treat and/ameliorate a 
tumor. These reagents can also be used in the preparation of 
10 well-tolerated by the host. The implant is placed in prox­
imity of a solid tumor for example, so that the local 
concentration of active agent is increased at that site relative 
to the rest of the body. 
A typical daily dosage might range from about 1 µg/kg to a medicament for use in treating a patient. Administration of 
other cancer therapeutic agents can occur prior to, concur­
rent with, or after administration with the immunoglobulin. 
Administration of the subject immunoglobulins can occur 
before, during or after surgical treatment, radiotherapy, 
hormone therapy, immunotherapy, hyperthermia, or other 
cancer treatment modality. Administration of the subject 
immunoglobulins can occur daily, weekly, or monthly as 
needed. Preferably, the immunoglobulins are administered 
weekly for one or more weeks. 
15 up to about 200 mg/kg subject weight or more, more 
preferably from about 0.01 mg/kg to about 150 mg/kg 
subject weight, more preferably from about 0.1 mg/kg to 
about 100 mg/kg subject weight, more preferably from 
about 1 mg/kg to about 75 mg/kg patient weight (and every 
20 integer value between these values) depending on the factors 
mentioned herein. Typically, the clinician will administer 
immunoglobulin until a dosage is reached that achieves the 
desired effect. The progress of this therapy can be easily 
Pharmaceutical compositions comprising the ligands can 
also include, if desired, pharmaceutically acceptable, non- 25 
toxic carriers or diluents, which are vehicles commonly used 
to formulate pharmaceutical compositions for animal or 
human administration. The diluent is selected so as not to 
affect the biological activity of the combination. Examples 
include but are not limited to distilled water, physiological 30 
phosphate-buffered saline, Ringer's solutions, dextrose solu­
tion, and Hank's solution. 
monitored by conventional assays. 
Although the present invention has been described in 
detail with reference to examples below, it is understood that 
various modifications can be made without departing from 
the spirit of the invention, and would be readily known to the 
skilled artisan. 
EXAMPLE 1 
EGFR is highly expressed in a variety of tumor types, and 
the preliminary data show that EGFR levels are sustained by 
Pgrmcl. As a result, Pgrmcl drives cell proliferation, at least 
in part via EGFR. Pgrmcl/Hpr6 activates multiple serine-
threonine kinases. To test the role of Pgrmcl in membrane­
associated signaling, Pgrmcl expression was inhibited by 
transfection with two separate siRNA oligonucleotide 
The agents of the invention can be formulated into 
preparations for injections by dissolving, suspending or 
emulsifying them in an aqueous or non-aqueous solvent, 35 
such as vegetable or other similar oils, synthetic aliphatic 
acid glycerides, esters of higher aliphatic acids or propylene 
glycol. The formulations may also contain conventional 
additives, such as solubilizers, isotonic agents, suspending 
agents, emulsifying agents, stabilizers and preservatives. 40 duplexes to distinct regions of the PGRMCl coding 
sequence. As a control, parallel cultures were transfected 
with a control siRNA called sicon. 
Suitable examples of sustained-release preparations 
include semipermeable matrices of solid hydrophobic poly­
mers containing the protein, which matrices are in the form 
of shaped articles, e.g., films, or microcapsules. Examples of 
sustained-release matrices include polyesters, hydrogels 45 
(e.g., poly(2-hydroxyethyl-methacrylate)) as described by 
Langer et al., J. Biomed. Mater. Res. 15: 167-277 (1981) and 
Langer, Chem. Tech. 12: 98-105 (1982) or poly(vinylalco­
hol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of 
L-glutamic acid and gamma ethyl-L-glutamate (Sidman et 50 
al., Biopolymers 22: 547-556, 1983), non-degradable ethyl­
ene-vinyl acetate (Langer et al., supra), degradable lactic 
acid-glycolic acid copolymers such as the LUPRON 
DEPOT™ (i.e., injectable microspheres composed of lactic 
acid-glycolic acid copolymer and leuprolide acetate), and 55 
poly-D-(-)-3-hydroxybutyric acid (EP 133,988). 
Sustained-release compositions also include liposomally 
entrapped ligand. Liposomes containing the ligand are pre­
pared by methods known per se. See, e.g., Epstein et al., 
Proc. Natl. Acad. Sci. USA 82: 3688-92 (1985); Hwang et 60 
al., Proc. Natl. Acad. Sci. USA 77: 4030-4 (1980); U.S. Pat. 
Nos. 4,485,045; 4,544,545; 6,139,869; and 6,027,726. Ordi­
narily, the liposomes are of the small ( about 200 to about 800 
Angstroms), unilamellar type in which the lipid content is 
greater than about 30 mole percent (mo!. % ) cholesterol; the 65 
selected proportion being adjusted for the optimal ligand 
therapy. 
In MDA-MB-468 cells, which over-express EGFR, trans­
fection with siPGR caused a nearly complete inhibition of 
EGFR levels. This was reflected in a 28-fold decrease in the 
predominant 180 kDa tyrosine phosphorylated band in 
MDA-MB-468 cells. As expected, Pgrmcl levels were 
almost completely inhibited. The DNA end-binding protein 
ku70 was used as a control for equal protein loading because 
no ku70 alterations were detected in these experiments. 
Pgrmcl did not affect EGFR transcription, because EGFR 
transcript levels were unchanged in siPGR-transfected cells, 
while Pgrmcl levels decreased. 
A second siRNA targeting Pgrmcl (which we will refer to 
as siPGR2), attenuated EGFR levels to a lesser extent. Using 
the siPGR2 siRNA, the levels of the 180 kDa tyrosine 
phosphorylated band were diminished, while ku70 was 
unaffected. 
EGFR drives proliferation of cancer cells through mul­
tiple pathways, and during the sub-culturing of Pgrmcl­
inhibited cells, it was immediately evident that the cells had 
diminished proliferation. When cell growth was tested by a 
time course, a 36% decrease in proliferation in Pgrmcl­
inhibited cells was detected. The decrease in proliferation 
was highly significant (P=0.0015 at day 5 and 0.0017 at day 
8). In this assay, cells in quadruplicate were counted during 
multiple stages of growth and stained viable cells by trypan 
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blue. The results are representative of a duplicate assay and inhibit the related Pgrmc2 and Neudesin proteins as well. It 
are consistent with multiple observations during sub-cultur- may be that inhibiting each of these proteins cumulatively 
ing. results in cell killing. 
The change in proliferation rate between sicon and The Pgrmcl Ligand AG-205 Mis-Localizes EGFR. 
siPGR-transfected cells was largely blocked with the EGFR 5 The model shows that Pgrmcl binds to Cavl to increase 
inhibitor AG1478. In this assay, cells were transfected with the transport of RTKs to the cell membrane and increase 
siRNA oligonucleotides, split into 96 well culture dishes and their stability within caveolae once localized to the cell 
treated with increasing doses of AG1478. Viability was membrane. One prediction of this model is that disrupting 
measured using the MTT assay. The results suggest that Pgrmcl function will cause RTKs to accumulate in an 
EGFR contributes to the increased growth rate of Pgrmcl- 10 intermediate state away from the cell membrane. 
To test this model, EGFR was stained by immunofluo­expressing cells. The data were generated using MDA-MB-
rescence 24 hours after treatment with 20 µM AG-205 in 
468 human breast cancer cells as a model system. The same MDA-MB-468 cells. In cells treated with the vehicle con-
phenotype in A549 human lung cancer cells was found, trol, EGFR localized to the cell membrane. In contrast, 
which showed decreased EGFR expression after treatment 15 EGFR localized to both the cell membrane and an intracel­
with RNAi to Pgrmcl. In addition, A549 cells demonstrated 
decreased growth in soft agar when expressing a stable 
shRNA targeting Pgrmcl. Thus, Pgrmcl stabilizes EGFR in 
multiple cell lines from more than one tissue of origin and 
lular ring which corresponds to the perinuclear region of the 
cell. Also, Pgrmcl may control the uptake from the mem­
brane to the perinuclear region. 
Thus, a mechanism has been found by which cancer cells 
affects the functional capacity of EGFR. 
There are four aromatic ligands for the Arabidopsis 
Pgrmcl homologue (Yoshitani et al., 2005), which is highly 
conserved with human Pgrmc 1 in the heme-I domain (Hand 
et al., 2003). The effect of the Pgrmcl ligand called AG-205 
20 stabilize RTKs and promote proliferation. This pathway is 
unusual in that the initiating protein is readily targeted by 
known ligands, and these ligands cause RTKs to be mis­
localized initially, subsequently leading to cell death. 
on EGFR stability and viability was tested. When MDA- 25 
MB-468 cells were treated with increasing doses of AG-205, 
a 12-50 µM dose induced a 14-fold decrease in EGFR levels. 
In contrast, a 12 µM dose of AG-205 increased Pgrmcl 
levels 4.8-fold, while doses of 25 and 50 µM decreased 
Pgrmcl to nearly undetectable levels. Ku70 levels were not 30 
affected by the AG-205 treatment. 
To assure that the results were not unique to the MDA­
MB-468 cell line, A549 lung cancer cells were also treated 
with increasing doses of AG-205. As for MDA-MB-468 
cells, AG-205 de-stabilized EGFR in a dose-dependent 35 
manner, with 20-50 µM AG-205 having the optimal activity. 
In contrast, AG-205 had little effect on the stability of the 
focal adhesion kinase or the Met receptor tyrosine kinase. 
Pgrmcl Ligand Inhibits Cell Growth in Cancer Cells. 
A 20 µM dose of AG-205 decreased EGFR levels and 40 
inhibited cancer cell viability. The 20 µM dose induced cell 
rounding and a marked loss of viability in both A549 and 
MDA-MB-468 cells. The growth inhibitory activity was 
dependent on the culture conditions, with AG-205 killing 
cells grown in low serum conditions but not 10% serum. The 45 
difference in viability was highly significant under these 
conditions (P=0.0006 for MDA-MB-468 cells at a dose of 
20 µM AG-205). While AG-205 induced a loss of viability, 
we did not detect an increase in cleavage of the poly ADP 
ribose polymerase (PARP) or caspase 3, suggesting that the 50 
cells were dying via an apoptotic mechanism. 
When ligand is abundant under normal culture conditions, 
lower doses ofEGFR are sufficient to maintain cell viability. 
AG-205 caused a slight increase in viability in MDA-MB-
468 cells. In MDA-MB-468 cells, EGF treatment induces 55 
apoptosis, and it is likely that, by reducing EGFR levels, 
AG-205 limits EGF-induced apoptosis and has a slight 
positive effect on viability. The results suggest that inhibit­
ing Pgrmcl with the AG-205 ligand causes EGFR to be 
Methodology for the Experiments 
Tissue culture. MDA-MB-468 cells were a kind gift from 
Dr. Rina Plattner of the University of Kentucky and were 
maintained in medium consisting of Dulbecco's Modified 
Eagle Medium containing 10% serum supreme (Fisher) and 
antibiotics. Cells were grown at 37° C. in 5% C02 in air. 
A549 and HCC827 lung cancer cells, as well as SK-Br-3 
breast cancer cells were obtained from the ATCC (American 
Type Culture Collection) and were grown under the same 
conditions. The H1650 lung cancer cell line was a kind gift 
from Dr. Heinz Kohler of the University of Kentucky. The 
Pgrmcl ligand AG-205 was purchased from Timtec, Inc. 
The EGFR inhibitor AG1478 was from Biomol, Inc. and 
was used at a concentration range of 0.8-40 µM. 
RNAi. For shRNA inhibition, the plasmids pGIPZ and 
V2LHS_90636, which is based on pGIPZ and drives the 
expression of an shRNA targeting Pgrmcl, were obtained 
from Open Biosystems, Inc. and purified using a Qiagen 
Maxi-prep purification kit. Viral vectors were produced by 
the Viral Vector Core at the Translational Core Laboratories, 
Cincinnati Children's Hospital Research Foundation, Cin­
cinnati, Ohio. For lentiviral infection, cells were split to a 
density of 500,000 cells/100 cm dish, allowed to attach 
overnight, and then were switched to medium containing 
0.1 % serum and infected with 6.4xl05 lentiviral particles in 
8 µg/ml polybrene (Chemicon, Inc.) overnight. The cells 
were then washed in fresh media, selected in 5 µg/ml 
puromycin for 5 days and checked for green fluorescence 
microscopically. 
Gene inhibition with siRNA transfected using Oligo­
fectamine (Invitrogen) was performed essentially as 
described (Crudden et al., (2006) J Pharmacol Exp Ther 
316:448-55; Mallory et al., (2005) Mo! Pharmacol 68: 1747-
56). To target Pgrmcl, an oligonucleotide duplex corre­
sponding to the 21 base pairs after position 509 in the 
Pgrmc 1 open reading frame was used. The duplex is referred 
de-stabilized, ultimately leading to cell death. 
AG-205 kills cancer cells while Pgrmcl RNAi does not. 
60 to as siPGR (Ambion, cat#16706, part#4392421). A second 
oligonucleotide duplex targeted a 21 base sequence at posi­
tion 559 in the Pgrmcl open reading frame and is referred 
to as "siPGR2". The control was the "control silencer #1" 
This is because RNAi is generally not a complete loss of 
function, and we were able to detect residual Pgrmcl 
transcription following both siRNA and shRNA, although 
transcription was greatly attenuated. There may also be 65 
Pgrmcl variants expressed that we were unable to detect. 
Secondly, RNAi inhibits only Pgrmcl, while AG-205 may 
(Ambion, cat#AM4635). 
Immunological techniques. Cells were extracted in RIPA 
buffer (50 mM Tris, pH 8.0, 1% Nonidet P-40, 150 mM 
NaCl, 0.5% sodium deoxycholate, 0.1 % sodium dodecyl 
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sulfate, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml of 
aprotinin, leupeptin and pepstatin) for standard western 
blotting. The antibodies used in the study were anti-caveo­
lin-1 (N-20, Santa Cruz Biologicals, # sc-894), anti-EGFR 
(1005, Santa Cruz, # sc-03), anti-ku70 (A-9, Santa Cruz # 5 
sc-5309), anti-Met (C-12, Santa Cruz # sc-10), anti-PARP 
(H-250, Santa Cruz # sc-7150), anti-phosphotyrosine 
(P-Tyr-100, Cell Signaling), anti-Pgrmcl (Novus Biologics) 
and anti-tubulin (Neomarkers). Some western blots for 
Pgrmcl were performed with a polyclonal antibody called 10 
anti-PGR-UKl which was raised in rabbits to an internal 10 
was placed in the lower chamber as a chemoattractant. Cells 
were allowed to invade for 16 hours at 37° C. Cells on the
upper surface of the membrane were removed, and cells on 
the undersurface were fixed, stained with 0.5% crystal violet 
in 20% methanol and counted. 
RT-PCR. Cells were harvested with trypsin, and RNA was 
purified, reverse transcribed with random hexamers, and 
amplified using Taq polymerase (GenScript, Piscataway, 
N.J.) in an Eppendorf Master Cycler (Eppendorf, Westbury, 
N.Y.) for 28-34 cycles of 94 ° C. for 1 minute., 55° C. for 1
minute., and 72° C. for 1 minute. PCR reactions contained
amino acid peptide. 
For immuno-precipitation, cells were plated at a density 
of 500,000 cells/dish in normal growth medium and left 
overnight. The next day, the cells were then scraped from the 
dish, washed in PBS and lysed in 1 % NP-40 buffer (1 % 
NP-40, 20 mM Tris, 150 mM NaCl, 5 mM EDTA, 1 mM 
Na3V04, pH 7.4, and 10 µg/ml of the protease inhibitors 
aprotinin and leupeptin) containing 1 mM Na3 V04. The 
lysates were divided into equal portions and immune-pre­
cipitated with protein A/G-agarose and various antibodies. 
After a 3 hour incubation, the agarose was pelleted by 
centrifugation and washed three times in 1 % NP-40 buffer. 
Immunofluorescence for EGFR was performed as 
described previously (Crudden et al., (2005) Tumour Biol 
26:142-6). Cells were grown on chamber slides, washed and 
fixed with 3.7% formaldehyde. The cells were then permea­
bilized with 0.1 % Triton X-100 in phosphate-buffered 
saline, blocked with 10% serum and incubated, in turn, with 
anti-EGFR 1005 and a Texas red-labeled anti-rabbit second­
ary antibody. 
Proliferation, anchorage-independent growth and migra­
tion assays. For growth curves, cells were plated in 24 well 
dishes and grown in 10% serum-containing medium. At 
various times, the cells were harvested with trypsin and fixed 
with formaldehyde added to a final concentration of 3.7%. 
Following the harvest of the final time point, the cells from 
each time point were counted using a Bright-line hemocy­
tometer (Hausser Scientific). 
MTT viability assays were performed as described pre­
viously. Briefly, cells were plated in 96-well tissue culture 
dishes and grown in various media with different drug doses. 
The cells were then incubated with 0.5 mg/ml of 3-[4,5-
dimethylthiazol-2-y]-2,5-diphenyltetrazolium bromide for 
1.5 hours, at which time the media was removed, the 
precipitated crystals were dissolved in dimethyl sulfoxide, 
and the absorbance at 590 nm was measured using a Bio-Tek 
µQuant spectrophotometer. 
primers to either EGFR, Pgrmcl, LDLR or PAii in combi­
nation with primers to actin, which served as an internal
control for cDNA loading. The primer sequences for EGFR
15 were EGFR+lOOF (ACGAGTAACAAGCTCACGCAG 
(SEQ ID NO: 1)) and EGFR+380R (TGCATCATAGTTA­
GATAAGAC (SEQ ID NO: 2)); the primers for PAii were 
PAI+90F (GTGGCCCACCTGGCCTCAGAC (SEQ ID 
NO: 3))and PAI+360R (GATCGCGTCTGTGGTGCTGA 
20 (SEQ ID NO: 4)); and the primers for LDLR were LDLR+ 
lOOF (TGCCAAGACGGGAAATGCATC (SEQ ID NO: 5)) 
and LDLR+379R (CGAACTGCCGAGAGATGCAC (SEQ 
ID NO: 6)). Pgrmcl was amplified with the primers HPR+ 
1080F and HPR+1370R, which have been described previ-
25 ously (Crudden et al., (2006) J Pharmacol Exp Ther 316: 
448-55) as have the actin primers (Cance et al., (1992) Surg
Oncol l:309-14). PCR products were visualized by electro­
phoresis in 2% agarose 1000 (Invitrogen).
Sucrose gradient fractionation. Caveolae fractionation 
30 was performed essentially as described (Liu et al. (1998) 
Biochem Biophys Res Commun 245:684-90). Cells were 
washed once with PBS, suspended in Tris lysis buffer (25 
mM Tris, pH 7.4, 250 mM sucrose and 2 mM EDTA) and 
lysed by dounce homogenization, passage through a 25 
35 gauge needle and three rounds of sonication. Lysates were 
then mixed with MBS buffer (25 mM MES, pH 6.5, 150 mM 
NaCl and 2 mM EDTA) containing 80% sucrose, mixed and 
overlaid in a SW41 rotor tube with MBS containing 35% 
sucrose and 5% sucrose. The gradient was centrifuged for 3 
40 hours at 175,000xg, and 1.2 ml fractions were collected. 
Results of the Experiments 
Pgrmcl stabilizes EGFR. Pgrmcl/Hpr6 activates multiple 
serine-threonine kinases. To test the role of Pgrmcl in 
membrane-associated signaling, Pgrmcl expression was 
45 inhibited by transfection with two separate siRNA oligo­
nucleotide duplexes to distinct regions of the Pgrmcl coding 
sequence. 
In MDA-MB-468 cells, which over-express EGFR, trans­
fection with siPGR caused a nearly complete inhibition of 
EGFR levels. This was reflected in a 28-fold decrease in the 
predominant 180 kDa tyrosine phosphorylated band in 
MDA-MB-468 cells. As expected, Pgrmcl levels were 
almost completely inhibited. The DNA end-binding protein 
ku70 was used as a control for equal protein loading because 
FACS was performed essentially as described previously 
(Mallory (2005)). Cells were trypsinized, washed and fixed 50 
in 70% ethanol, then stained in 20 µg/ml propidium iodide 
containing 50 µg/ml DNase-free RNase. FACS analysis was 
performed at the University of Kentucky flow cytometry 
facility, and the data were analyzed using Modfit software 
(Verity, Inc.). 55 no ku70 alterations were detected in these experiments. 
For soft agar assays, cells were resuspended in 0.4% agar 
in DMEM at a density of 200 cells/ml and overlaid on 1 % 
agar, which was also dissolved in lxDMEM. Cells were 
plated in triplicate, and the assay was performed at least two 
separate times. Cells were grown for approximately 2 weeks 60 
and imaged using an Olympus IX70 microscope. The perim­
eters of 30-35 different colonies were calculated using 
Pictureframe 2.3 software (Optronics, Inc.). 
To assay migration, serum-starved shRNA-expressing 
cells were suspended in DMEM containing 1 % bovine 65 
serum albumin and placed in the top well of invasion 
chambers (BD Biosciences). Medium containing 10% serum 
Pgrmcl did not affect EGFR transcription, because EGFR 
transcript levels were unchanged in siPGR-transfected cells, 
while Pgrmcl levels decreased. 
A second siRNA targeting Pgrmcl (which we will refer to 
as siPGR2), attenuated EGFR levels to a lesser extent. Using 
the siPGR2 siRNA, the levels of the 180 kDa tyrosine 
phosphorylated band were diminished, while ku70 was 
unaffected. 
EGFR drives proliferation of cancer cells through mul­
tiple pathways, and we detected a 36% decrease in prolif­
eration in Pgrmcl-inhibited cells. The decrease in prolifera­
tion was highly significant (P=0.0015 at day 5 and 0.0017 at 
US 9,724,337 B2 
21 
day 8). The change in proliferation rate between siCON and 
siPGR-transfected cells was largely blocked with the EGFR 
inhibitor AG1478, suggesting that EGFR contributes to the 
increased growth rate of Pgrmcl-expressing cells. 
Pgrmcl stabilizes EGFR in lung cancer cells. In A549 5 
lung cancer cells, Pgrmcl inhibition by shRNA caused a 
4.1-fold reduction in EGFR levels, with no change in Met. 
22 
alone or in combination with AG-205. AG-1478 induced a 
25% decrease in viability, while AG-205 was toxic to 47% 
of the cells, and the combination of the two drugs was not 
As expected, Pgrmcl levels were inhibited, but tubulin 
levels were not. Reduced EGFR levels could arise from 
altered transcription or post-transcriptional events. How­
ever, EGFR transcript levels were unchanged after Pgrmcl 
was inhibited. 
significantly different from that of AG-205 (P=0.31, t-test). 
The results support the model that AG-1478 and AG-205 
function through a common mechanism, which includes 
EGFR. The toxicity of AG-205 is also dependent on Pgrmc 1, 
because Pgrmcl-inhibited A549 cells exhibited decreased 
toxicity to AG-205 (P=0.0001, t-test). This experiment was 
10 analyzed after 36 hours, and after a longer incubation, both 
cell types exhibited loss of viability. 
The shPGR short hairpin targeted a sequence in the end of 
the 3' untranslated region of the Pgrmcl transcript. A549 
cells infected with the Lv-shPGR lentivirus were transfected 15 
with either a control plasmid or a plasmid expressing a form 
Structural features of EGFR appear to be important for the 
growth inhibiting activity of AG-205. In A549 and MDA­
MB-468 cells, AG-205 efficiently inhibited cell growth, and 
both cell lines express the wild-type form of EGFR (Table 
1). NIH-3T3 cells also express the wild-type EGFR and 
were inhibited by AG-205 (Table 1). In contrast, HCC827 
and H1650 cells, which express a llE746-A750 deletion 
of Pgrmcl that lacked the 3' untranslated region 
(Pgrmclll3'). A549 cells transfected with the control plas­
mid maintained a low level of EGFR, while EGFR was 
elevated in cells expressing Pgrmclll3', which was con­
firmed by western blot. Thus, EGFR levels are dependent on 
Pgrmcl expression. 
20 mutant of EGFR, were relatively insensitive to AG-205 
inhibition (Table 1). SK-Br-3 cells, which express modest 
amounts of EGFR but extremely high levels of HER2/neu, 
were also relatively insensitive to AG-205 (Table 1). The 
results suggest that, in the cell lines tested, alterations in 
25 EGFR activation or binding partners can overcome AG-205 
EGFR promotes growth and adhesion of lung cancer 
cells, and we tested the extent to which these properties were 
altered when Pgrmcl was inhibited. A549/GIPZ and A549/ 
shPGR cells grew at equivalent rates, and we did not detect 
any change in their cell cycle profile by FACS analysis. In 
contrast, growth in soft agar differed markedly between the 
two cell populations. A549/GIPZ cells readily formed colo­
nies in soft agar, while A549/shPGR cells formed small 
microcolonies that failed to proliferate. The radii of 30 
colonies from each cell population were measured, and 
A549/GIPZ colonies were 2.9-fold larger, a difference that 
was highly significant (P=6xl0-13, t-test). A box plot of the
data in In addition, migration in A549/GIPZ cells was 35 
4.4-fold higher than that of A549/shPGR cells, an effect that 
was highly significant (P=0.002, t-test). Thus, Pgrmcl 
increases anchorage independent growth and migration. 
sensitivity. 
The model is that high EGFR expression is required for 
maintaining viability under low serum conditions, perhaps 
30 via paracrine signaling. When ligand is abundant under 
40 
normal culture conditions, lower doses of EGFR are suffi­
cient to maintain cell viability. Interestingly, AG-205 caused 
a slight increase in viability in MDA-MB-468 cells. In 
MDA-MB-468 cells, EGF treatment induces apoptosis 
(Armstrong et al., (1994) Cancer Res 54:5280-3), and it is 
likely that, by reducing EGFR levels, AG-205 limits EGF­
induced apoptosis and has a slight positive effect on viabil­
ity. A Pgrmcl ligand inhibits EGFR stability. There are four 
aromatic ligands for the Arabidopsis Pgrmcl homologue, 
which is highly conserved with human Pgrmcl in the Pgrmcl maintains EGFR at the cell membrane, and the 
heme-I domain. The effect of the Pgrmcl ligand called localization of EGFR in AG-205-treated cells after 24 hours 
AG-205 on EGFR stability and viability was tested. When was tested. Surprisingly, EGFR localized to the perinuclear 
MDA-MB-468 cells were treated with increasing doses of region of the cell, similar to its localization after RNAi 
AG-205, a 12-50 µM dose induced a 14-fold decrease in 45 inhibition. 
EGFR levels. In contrast, a 12 µM dose of AG-205 increased 
Pgrmcl levels 4.8-fold, while doses of 25 and 50 µM 
decreased Pgrmcl to nearly undetectable levels. Ku70 levels 
were not affected by the AG-205 treatment. The results were 
not specific for MDA-MB-468 cells, because EGFR was 
also inhibited by AG-205 in A549 cells, while tyrosine 
kinase FAK and ku70 were unaffected. 
A 20 µM dose of AG-205 inhibited cancer cell viability 
72-96 hours after treatment. The 20 µM dose induced cell
rounding and a marked loss of viability in both MDA-MB-
468 and A549 cells. The growth inhibitory activity was
dependent on the culture conditions, with AG-205 killing
cells grown in low serum conditions but not 10% serum. The
difference in viability was highly significant under these
conditions (P=0.0006 for MDA-MB-468 cells at a dose of
20 µM AG-205). While AG-205 induced a loss of viability,
we did not detect an increase in cleavage of the poly ADP
ribose polymerase (PARP) or caspase 3, suggesting that the
cells were dying via an apoptotic mechanism.
50 
55 
60 
Because AG-205 inhibited EGFR levels and cell viability, 65
the extent to which the two effects were related was tested. 
A549 cells were treated with the EGFR inhibitor AG-1478, 
TABLE I 
IC50 values for AG-205 in various cell lines 
Cell line Tissue of origin Serum-starved (µM) EGFR 
A431 epitheloid wild-type 
MDA-MB-231 breast 18 wild-type 
MDA-MB-468 breast 12 wild-type 
A549 lung 15 wild-type 
H157 lung 10 wild-type 
H358 lung 12 wild-type 
H1650 lung >100 L\.E746-A750 
HCC827 lung >100 L\.E746-A750 
It will be appreciated that, although specific embodiments 
of the invention have been described herein for purposes of 
illustration, various modifications may be made without 
departing from the spirit and the scope of the invention. 
Accordingly, the invention is not limited except as by the 
appended claims. 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 8 
<210> SEQ ID NO 1 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 1 
acgagtaaca agctcacgca g 
<210> SEQ ID NO 2 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 2 
tgcatcatag ttagataaga c 
<210> SEQ ID NO 3 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 3 
gtggcccacc tggcctcaga c 
<210> SEQ ID NO 4 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 4 
gatcgcgtct gtggtgctga 
<210> SEQ ID NO 5 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 5 
tgccaagacg ggaaatgcat c 
<210> SEQ ID NO 6 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 
cgaactgccg agagatgcac 
24 
21 
21 
21 
20 
21 
20 
<210> SEQ ID NO 7 
<211> LENGTH, 54 
<212> TYPE, PRT 
25 
<213> ORGA NISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
polypeptide 
<400> SEQUENCE, 7 
Ala Ile Asn Gly Lys Val Phe Asp Val Thr Lys Gly Arg Lys Phe Tyr 
1 5 10 15 
Gly Pro Glu Gly Pro Tyr Gly Val Phe Ala Gly Arg Asp Ala Ser Arg 
20 25 30 
Gly Leu Thr Leu Ser Asp Trp Glu Ser Gln Phe Thr Phe Lys Tyr His 
35 40 45 
His Val Gly Lys Leu Leu 
50 
<210> SEQ ID NO 8 
<211> LENGTH, 54 
<212> TYPE, PRT 
<213> ORGA NISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
polypeptide 
<400> SEQUENCE, 8 
Ala Ile Lys Gly Arg Val Phe Asp Val Thr Thr Gly Lys Ser Phe Tyr 
1 5 10 15 
Gly Ser Gly Gly Asp Tyr Ser Met Phe Ala Gly Lys Asp Ala Ser Arg 
20 25 30 
Ala Leu Thr Leu Asn Asp Trp Glu Thr Lys Phe Glu Ala Lys Tyr Pro 
35 40 45 
Val Val Gly Arg Val Val 
50 
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What is claimed is: 
1. A method for inhibiting growth of a tumor and/or
metastatic progression thereof in a human subject in need 
thereof comprising administering a compound named 
AG-205 consisting of the following formula 
40 
3. The method of claim 1, wherein the subject is admin­
isteredAG-205 in an amount of0.1 mg/kg subject weight to 
100 mg/kg subject weight. 
l;k-o-c, 
N�
S 
0 
to the human subject in need thereof in an amount 
sufficient to inhibit growth of the tumor and/or meta­
static progression thereof, 
wherein the tumor comprises breast cancer cells over­
expressing progesterone receptor membrane compo­
nent-I and wild type epidermal growth factor receptor, 
wherein AG-205 destabilizes the epidermal growth 
factor receptor. 
2. The method of claim 1, wherein the tumor is a primary
tumor or a metastatic lesion. 
4. The method of claim 1, wherein the metastatic pro-
45 gression is to brain, lung, liver, or bone. 
50 
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5. A method for inhibiting growth of a tumor and/or
metastatic progression thereof in a human subject in need 
thereof comprising administering a compound named 
AG-205 consisting_of the following formula 
to the human subject in need thereof in an amount sufficient 
to inhibit growth of the tumor and/or metastatic progression 
65 thereof, administering a chemotherapeutic agent, and further 
administering an immunotherapeutic agent and/or radiation 
therapy, wherein the tumor comprises breast cancer cells 
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over-expressing progesterone receptor membrane compo­
nent-I and wild type epidermal growth factor receptor, and 
wherein the AG-205 destabilizes the epidermal growth fac­
tor receptor. 
6. The method of claim 5, wherein AG-205 is adminis- 5
tered intravenously, intrathecally, or subcutaneously to the 
subject in need thereof. 
7. The method of claim 5, wherein AG-205 is adminis­
tered in an amount of 1 mg/kg subject weight to 100 mg/kg 
subject weight. 10 
8. The method of claim 5, wherein AG-205 is adminis­
tered daily, weekly, or monthly. 
* * * * * 
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